NCT00797706View on ClinicalTrials.gov

Phase I/II Dose Ranging CHRONSEAL® Study in Venous Leg Ulcers

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Chronic Venous Leg Ulcers
Interventions
DRUG

CHRONSEAL

Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions

Trial Locations (16)

2317

Medi 3 Innlandet AS, Department Hamar, Hamar

2402

Medi3 Innlandet AS, Department Elverum, Elverum

6807

Hudavdelingen Helse, Førde

0369

Colosseumklinikken, Oslo

342 30

Vårdcentralen Alvesta, Alvesta

SE-182 88

Danderyds Sjukhus AB, Danderyd

SE-122 45

Carema Vårdcentral Gubbängen, Enskede

SE-301 85

Department of Dermatology and Infectious diseases, Halmstad

SE-434 30

Husläkarna i Kungsbacka, Kungsbacka

SE-221 85

Department of Dermatology, Lund University hospital, Lund

SE-205 02

Department of Dermatology, University Hospital MAS, Malmo

SE-111 29

Gamla Stans Vårdcentral, Stockholm

SE-115 26

Taptogatans Husläkare, Stockholm

SE-901 85

Department of Dermatology, Norrlands University hospital, Umeå

SE-751 05

Department of Medical Sciences, Section of Dermatology and Venereology, Uppsala University hospital, Uppsala

SE-432 44

Neptunuskliniken, Varberg

Sponsors

Collaborators (1)

Kringle Pharma, Inc.
All Listed Sponsors
collaborator

Kringle Pharma, Inc.

INDUSTRY

lead

Kringle Pharma Europe AB

INDUSTRY